ENTRY       D11595                      Drug
NAME        Belantamab mafodotin (USAN);
            Belantamab mafodotin (genetical recombination) (JAN);
            Belantamab mafodotin-blmf;
            Blenrep (TN)
PRODUCT     BLENREP (GlaxoSmithKline LLC)
FORMULA     C6484H10008N1728O2030S44. (C49H66N6O11)4
EXACT_MASS  149625.9884
MOL_WEIGHT  149718.3897
REMARK      ATC code: L01FX15
            Product: D11595<US>
EFFICACY    Antineoplastic
  DISEASE   Multiple myeloma [DS:H00010]
  TYPE      Antibody-drug conjugate
COMMENT     Treatment of multiple myeloma
TARGET      TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
            TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  PATHWAY   hsa04060(608)  Cytokine-cytokine receptor interaction
            hsa04672(608)  Intestinal immune network for IgA production
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX15 Belantamab mafodotin
                  D11595  Belantamab mafodotin (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Belantamab Mafodotin
                D11595  Belantamab mafodotin (USAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Tumor necrosis factor receptors
                TNFRSF17 (BCMA, CD269)
                 D11595  Belantamab mafodotin (USAN) &lt;US&gt;
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                TUBB
                 D11595  Belantamab mafodotin (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11595
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11595
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11595
DBLINKS     PubChem: 405226462
///
